BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25699704)

  • 1. A new path to leukemia with WIT.
    Sardina JL; Graf T
    Mol Cell; 2015 Feb; 57(4):573-574. PubMed ID: 25699704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation.
    Wang Y; Xiao M; Chen X; Chen L; Xu Y; Lv L; Wang P; Yang H; Ma S; Lin H; Jiao B; Ren R; Ye D; Guan KL; Xiong Y
    Mol Cell; 2015 Feb; 57(4):662-673. PubMed ID: 25601757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.
    Rampal R; Alkalin A; Madzo J; Vasanthakumar A; Pronier E; Patel J; Li Y; Ahn J; Abdel-Wahab O; Shih A; Lu C; Ward PS; Tsai JJ; Hricik T; Tosello V; Tallman JE; Zhao X; Daniels D; Dai Q; Ciminio L; Aifantis I; He C; Fuks F; Tallman MS; Ferrando A; Nimer S; Paietta E; Thompson CB; Licht JD; Mason CE; Godley LA; Melnick A; Figueroa ME; Levine RL
    Cell Rep; 2014 Dec; 9(5):1841-1855. PubMed ID: 25482556
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Pasca S; Jurj A; Tomuleasa C; Zdrenghea M
    Medicina (Kaunas); 2020 Nov; 56(12):. PubMed ID: 33255417
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical remission following ascorbate treatment in a case of acute myeloid leukemia with mutations in TET2 and WT1.
    Das AB; Kakadia PM; Wojcik D; Pemberton L; Browett PJ; Bohlander SK; Vissers MCM
    Blood Cancer J; 2019 Oct; 9(10):82. PubMed ID: 31578317
    [No Abstract]   [Full Text] [Related]  

  • 6. TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns.
    Damm F; Markus B; Thol F; Morgan M; Göhring G; Schlegelberger B; Krauter J; Heuser M; Bernard OA; Ganser A
    Genes Chromosomes Cancer; 2014 Oct; 53(10):824-32. PubMed ID: 24898826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics.
    Cagnetta A; Adamia S; Acharya C; Patrone F; Miglino M; Nencioni A; Gobbi M; Cea M
    Leuk Res; 2014 Jun; 38(6):649-59. PubMed ID: 24726781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
    Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
    J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical loss of 5-hydroxymethylcytosine expression in acute myeloid leukaemia: relationship to somatic gene mutations affecting epigenetic pathways.
    Magotra M; Sakhdari A; Lee PJ; Tomaszewicz K; Dresser K; Hutchinson LM; Woda BA; Chen BJ
    Histopathology; 2016 Dec; 69(6):1055-1065. PubMed ID: 27458708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia.
    Ponciano-Gómez A; Martínez-Tovar A; Vela-Ojeda J; Olarte-Carrillo I; Centeno-Cruz F; Garrido E
    Tumour Biol; 2017 Oct; 39(10):1010428317732181. PubMed ID: 28992762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.
    Liu WJ; Tan XH; Luo XP; Guo BP; Wei ZJ; Ke Q; He S; Cen H
    Leuk Lymphoma; 2014 Dec; 55(12):2691-8. PubMed ID: 24524305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
    Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
    Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
    Wang R; Gao X; Yu L
    BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tet oncogene family member 2 gene alterations in childhood acute myeloid leukemia.
    Li MJ; Yang YL; Lee NC; Jou ST; Lu MY; Chang HH; Lin KH; Peng CT; Lin DT
    J Formos Med Assoc; 2016 Sep; 115(9):801-6. PubMed ID: 26414667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia.
    Yamazaki J; Taby R; Jelinek J; Raynal NJ; Cesaroni M; Pierce SA; Kornblau SM; Bueso-Ramos CE; Ravandi F; Kantarjian HM; Issa JP
    J Natl Cancer Inst; 2015 Nov; 108(2):. PubMed ID: 26568194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features and prognosis of normal karyotype acute myeloid leukemia pediatric patients with WT1 mutations: an analysis based on TCGA database.
    Xu J; Zhang Y; Hu J; Ren Y; Wang H
    Hematology; 2020 Dec; 25(1):79-84. PubMed ID: 32019476
    [No Abstract]   [Full Text] [Related]  

  • 17. Landscape of TET2 mutations in acute myeloid leukemia.
    Weissmann S; Alpermann T; Grossmann V; Kowarsch A; Nadarajah N; Eder C; Dicker F; Fasan A; Haferlach C; Haferlach T; Kern W; Schnittger S; Kohlmann A
    Leukemia; 2012 May; 26(5):934-42. PubMed ID: 22116554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.
    Cher CY; Leung GM; Au CH; Chan TL; Ma ES; Sim JP; Gill H; Lie AK; Liang R; Wong KF; Siu LL; Tsui CS; So CC; Wong HW; Yip SF; Lee HK; Liu HS; Lau JS; Luk TH; Lau CK; Lin SY; Kwong YL; Leung AY
    Blood Cancer J; 2016 Jul; 6(7):e442. PubMed ID: 27391574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Friend or foe? The case of Wilms' Tumor 1 (WT1) mutations in acute myeloid leukemia.
    Awada H; Durmaz A; Gurnari C; Kishtagari A; Zawit M; Pagliuca S; Visconte V
    Blood Cells Mol Dis; 2021 May; 88():102549. PubMed ID: 33636567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
    Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
    J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.